Cell-selective targeting of immune cells

About this project

Systemic treatment with immunomodulatory drugs can lead to systemic side effects. Liposomal or synthetic nanocarriers are capable to deliver active substances directly into target cells. To address specific cell types, nanocarriers are functionalized to allow a cell-selective targeting.  This project aims to test nanocarriers as target strategy for myeloid cells. Using cell-selective targeting approaches to conduct active agents into target cells, systemic side effects can be minimized while local effective dosages can be increased.

Funding

German Federal Ministry of Economics and Technology (BMWi), via the Consortium of Industrial Research Associations (AiF), ZIM Program, Grant KF2531702AJ3; DFG, German Research Foundation grant SFB900; Germany's Excellence Strategy – EXC 2155 “RESIST”